Remove Analysis Remove Medicare Remove mHealth Remove Telehealth
article thumbnail

Patient monitoring is evolving with artificial intelligence, sensors, smart technology, more

Healthcare IT News - Telehealth

"To extract actionable information from this data, healthcare providers are turning to big data analytics and other analysis solutions. "The data explosion can be harnessed and employed through technologies such as Artificial Intelligence (AI), machine learning, etc., to deliver targeted, outcome-based therapies."

mHealth 163
article thumbnail

The Importance of Broadband and Net Neutrality for Health, to the Last Person and the Last Mile

Health Populi

There is indeed improvement, Brookings’ analysis found, but millions of people still lack broadband access…separate from the issue of net neutrality. These three maps illustrate the inconsistent growth rates across metro areas in the U.S, leaving many people “in the digital dark,” the authors note.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

2019 CMS Fee Schedule Expands Reimbursement for Remote Care

care innovations

It’s official: The Centers for Medicare & Medicaid Services (CMS) 2019 fee schedule is in effect as of January 1, 2019, bringing with it three new CPT codes that allow for expanded reimbursement for remote care services. He adds that they also “mark an important step in the government's acceptance of mHealth and telehealth technology.”.

article thumbnail

A Mid-Year Update on 2023 Healthcare Trends

Henry Kotula

Some telehealth flexibilities that were allowed under the PHE are also staying in effect, at least until the end of 2024. Declining Margins at Hospitals: Previous analysis by the consulting firm Kaufman Hall predicted that more than half of all hospitals would have negative margins at the end of 2022.

article thumbnail

The The Five Biggest Areas of Opportunity for Digital Health

The Digital Health Corner

A landmark clinical trial in which drugs are given solely on the basis of genetic markers identified in the cancer tissue itself is the NCI-MATCH Trial (Molecular Analysis for Therapy Choice).